Half-year report · HY

Period2025-10-01 → 2026-03-31
Filed2026-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥18.9bn2025-10-01 → 2026-03-31Cons.Net sales
Revenue¥34.4bn2024-10-01 → 2025-09-30Cons.Net sales (5-year summary)
Revenue¥17.8bn2024-10-01 → 2025-03-31Cons.Net sales
Operating income¥530m2025-10-01 → 2026-03-31Cons.Operating income
Operating income¥325m2024-10-01 → 2025-03-31Cons.Operating income
Ordinary income¥565m2025-10-01 → 2026-03-31Cons.Ordinary income
Ordinary income¥595m2024-10-01 → 2025-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥355m2024-10-01 → 2025-03-31Cons.Ordinary income
Profit before tax¥576m2025-10-01 → 2026-03-31Cons.Income before income taxes
Profit before tax¥400m2024-10-01 → 2025-03-31Cons.Income before income taxes
Net income (owners)¥396m2025-10-01 → 2026-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥429m2024-10-01 → 2025-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥269m2024-10-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income¥400m2025-10-01 → 2026-03-31Cons.Profit loss
Net income¥273m2024-10-01 → 2025-03-31Cons.Profit loss
Total assets¥20.4bnat 2026-03-31Cons.Assets
Total assets¥18.4bnat 2025-09-30Cons.Assets
Total assets¥18.5bnat 2025-03-31Cons.Total assets (5-year summary)
Total liabilities¥11.8bnat 2026-03-31Cons.Liabilities
Total liabilities¥10.4bnat 2025-09-30Cons.Liabilities
Net assets / equity¥8.5bnat 2026-03-31Cons.Net assets
Net assets / equity¥8.0bnat 2025-09-30Cons.Net assets
Net assets / equity¥7.7bnat 2025-03-31Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2026-03-31Cons.Cash and deposits
Cash and deposits¥925mat 2025-09-30Cons.Cash and deposits
Cash & equivalents¥3.7bnat 2026-03-31Cons.Cash and cash equivalents
Cash & equivalents¥911mat 2025-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.5bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥745mat 2024-09-30vCons.Cash and cash equivalents
Operating cash flow¥2.9bn2025-10-01 → 2026-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥150m2024-10-01 → 2025-09-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥674m2024-10-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥33m2025-10-01 → 2026-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥19m2024-10-01 → 2025-09-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥62m2024-10-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥53m2025-10-01 → 2026-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3m2024-10-01 → 2025-09-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥6m2024-10-01 → 2025-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥439.522025-10-01 → 2026-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥475.932024-10-01 → 2025-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥298.42024-10-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio41.5%at 2026-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio43.0%at 2025-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio40.9%at 2025-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Academia Life Science Sales Groupreportable segmentrevenue2025-10-01 → 2026-03-31¥1.3bn
Academia Life Science Sales Groupreportable segmentrevenue external2025-10-01 → 2026-03-31¥1.3bn
Industry Sales Groupreportable segmentrevenue2025-10-01 → 2026-03-31¥9.6bn
Industry Sales Groupreportable segmentrevenue external2025-10-01 → 2026-03-31¥9.6bn
Medical Sales Groupreportable segmentrevenue2025-10-01 → 2026-03-31¥8.0bn
Medical Sales Groupreportable segmentrevenue external2025-10-01 → 2026-03-31¥8.0bn
—segment totalrevenue2025-10-01 → 2026-03-31¥18.9bn
—segment totalrevenue external2025-10-01 → 2026-03-31¥18.9bn
Academia Life Science Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥1.5bn
Academia Life Science Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥1.5bn
Industry Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥9.1bn
Industry Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥9.1bn
Medical Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥7.2bn
Medical Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥7.2bn
—segment totalrevenue2024-10-01 → 2025-03-31¥17.8bn
—segment totalrevenue external2024-10-01 → 2025-03-31¥17.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)太陽有限責任監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)島 川 行 正
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)今  井  裕  之
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1InterimDuration17806883000JPY
Net sales (5-year summary)InterimDuration18942154000JPY
Net sales (5-year summary)Prior1YearDuration34442625000JPY
Ordinary income loss (5-year summary)Prior1InterimDuration354966000JPY
Ordinary income loss (5-year summary)InterimDuration564524000JPY
Ordinary income loss (5-year summary)Prior1YearDuration595147000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1InterimDuration268852000JPY
Profit loss attributable to owners of parent (5-year summary)InterimDuration395980000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration428799000JPY
Comprehensive income (5-year summary)Prior1InterimDuration240775000JPY
Comprehensive income (5-year summary)InterimDuration630459000JPY
Comprehensive income (5-year summary)Prior1YearDuration606808000JPY
Net assets (5-year summary)Prior1InterimInstant7652750000JPY
Net assets (5-year summary)InterimInstant8537122000JPY
Net assets (5-year summary)Prior1YearInstant8019651000JPY
Total assets (5-year summary)Prior1InterimInstant18476746000JPY
Total assets (5-year summary)InterimInstant20352502000JPY
Total assets (5-year summary)Prior1YearInstant18422827000JPY
Basic earnings loss per share (5-year summary)Prior1InterimDuration298.40
Basic earnings loss per share (5-year summary)InterimDuration439.52
Basic earnings loss per share (5-year summary)Prior1YearDuration475.93
Diluted earnings per share (5-year summary)Prior1InterimDuration-
Diluted earnings per share (5-year summary)InterimDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1InterimInstant0.409
Equity to asset ratio (5-year summary)InterimInstant0.415
Equity to asset ratio (5-year summary)Prior1YearInstant0.430
Net cash provided by used in operating activities (5-year summary)Prior1InterimDuration674188000JPY
Net cash provided by used in operating activities (5-year summary)InterimDuration2874136000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration149878000JPY
Net cash provided by used in investing activities (5-year summary)Prior1InterimDuration62144000JPY
Net cash provided by used in investing activities (5-year summary)InterimDuration-32554000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration19081000JPY
Net cash provided by used in financing activities (5-year summary)Prior1InterimDuration6484000JPY
Net cash provided by used in financing activities (5-year summary)InterimDuration-52743000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration-2950000JPY
Cash and cash equivalents (5-year summary)Prior1InterimInstant1487404000JPY
Cash and cash equivalents (5-year summary)InterimInstant3699435000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant910596000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember960000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember960000
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant960000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant960000
Number of shares heldInterimInstant_No1MajorShareholdersMember89600
Shareholding ratioInterimInstant_No1MajorShareholdersMember0.099

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-09-30pass
balance sheet identityconsolidated 2026-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-09-30pass
statement vs summary · net assetsconsolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-10-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-10-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-10-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-10-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-10-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-10-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass
statement vs summary · total assetsconsolidated 2026-03-31pass